LUZP2 Inhibition Sensitizes Prostate Cancer to Chemotherapy by Suppressing RAD50

Xin L, Na-Er S, Jing-Lan H, Ping G and Xiao-Ming D

College of Life Sciences, Shaanxi Normal University, China
These authors contributed equally to this work

^*Correspondance to: Ping Gao 

 PDF  Full Text Research Article | Open Access

Abstract:

Background: Prostate cancer is the most frequent malignancy in the worldwide male population. The expression of LUZP2 in human tissues has marked tissue specificity, mainly in the brain, adrenal gland and prostate. However, the chemosensitivity of LUZP2 in prostate cancer cells to drugs is unclear. In this study, the role of LUZP2 in paclitaxel resistance in prostate cancer was therefore investigated. Methods: LUZP2 and RAD50 protein expression in DU145 or PC3 cells was examined by western blotting. The rates of cell apoptosis were measured by an Annexin V-FITC/PI Apoptosis Detection Kit. Cell proliferation was measured by CCK8 and colony formation assay. Cell migration ability was tested by wound healing assay. Results: LUZP2 overexpression diminished the chemosensitivity of prostate cancer cells to paclitaxel, inhibition LUZP2 expression enhanced the chemosensitivity of prostate cancer cells to paclitaxel. Mechanistically, the expression of LUZP2 was positively correlated with RAD50 level, and LUZP2 regulated the mRNA and protein levels of RAD50. In addition, RAD50 knockdown also increased the chemosensitivity of prostate cancer cells to paclitaxel, and RAD50 overexpression reversed the promoting effect of LUZP2 inhibition on the chemosensitivity of prostate cancer cells to paclitaxel. Conclusion: Our results demonstrated that LUZP2 knockdown could increase the chemosensitivity of prostate cancer cells to paclitaxel by suppressing RAD50.

Keywords:

Prostate cancer; LUZP2; RAD50; Chemotherapy

Cite the Article:

Xin L, Na-Er S, Jing-Lan H, Ping G, Xiao-Ming D. LUZP2 Inhibition Sensitizes Prostate Cancer to Chemotherapy by Suppressing RAD50. Clin Oncol. 2024;9:2049..